©2025 Stanford Medicine
IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
Recruiting
Trial ID: NCT06087029
Purpose
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.
Official Title
IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
Stanford Investigator(s)
Dominik Fleischmann
Professor of Radiology (Cardiovascular Imaging)
Eligibility
Inclusion Criteria:
1. Age \> 21 years
2. Stanford type B aortic dissection not involving the aorta at or proximal to the innominate artery, without rupture and/or malperfusion (renal, mesenteric, or extremity)
3. Acuity: within 48 hours - 6 weeks of index admission
4. Ability to provide written informed consent and comply with the protocol
5. Investigator believes anatomy is suitable for TEVAR
Exclusion Criteria:
1. Ongoing systemic infection
2. Pregnant or planning to become pregnant in the next 3 months
3. Life expectancy related to non-aortic conditions \< 2 years
4. Unwilling or unable to comply with all study procedures including serial imaging follow-up
5. Known patient history of genetic aortopathy
6. Penetrating Aortic Ulcer and Intramural hematoma
7. Iatrogenic (traumatic) aortic dissection
8. Prior surgery for aortic dissection
Intervention(s):
procedure: TEVAR
other: Guideline directed medical therapy and surveillance of dissection
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305